LAG3 and neoplasm: The exploration of the immunological response to nivolumab plus relatlimib showed the following: higher IFN-γ level increases compared to baseline for nivolumab plus relatlimab compared to nivolumab alone [108]; decreased sLAG-3 levels in patients treated with nivolumab plus relatlimab [108]; higher baseline PD1+CD8+ and ICOS1+CD8+ T cells in responders to nivolumab plus relatlimab [109]; and a better response to nivolumab plus relatlimab and nivolumab alone in patients exhibiting higher LAG-3 tumor expression [109].